HHistocell
Histocell is a Basque biopharmaceutical company and CDMO in regenerative medicine, founded in 2004 as a spin-off of the University of the Basque Country (UPV/EHU) and based at the Bizkaia Science and Technology Park in Derio, near Bilbao. It develops and manufactures advanced therapy medicinal products (adipose-derived mesenchymal stem cell therapies for bone regeneration, spinal cord injury and stress urinary incontinence) alongside a second business unit of medical devices and dermocosmetic products for wound healing, and offers GMP-grade contract manufacturing from its authorised ATMP facility in Larrabetzu. It has raised roughly €9M since 2006 from institutional and private investors, obtained GMP certification in October 2025 for clinical-grade iPSC cell banks with partner REPROCELL, and began clinical trials for stress urinary incontinence in May 2025.
Founders
Global models 4
R
E
C
OIn the same niche 8 others
See all in the Start-ups Map →
Notes: Most funded first
Investors 6
Open as list →
S
R
IFunding rounds 4
| Date | Round | Amount | Lead |
|---|---|---|---|
| 2022-11-07 | No stage disclosed | €0.4M | ReproCELL |
| 2018-09 | Series B (estimated) | €3M | Cell Innovation Partners |
| 2016-09-29 | Series A (estimated) | €4M |
Lead not disclosed
+1 more
|
| 2015-06-11 | Seed (estimated) | €2.5M |
Lead not disclosed
+1 more
|